IMTX
Price
$10.57
Change
+$0.40 (+3.93%)
Updated
Oct 15, 11:16 AM (EDT)
Capitalization
1.24B
33 days until earnings call
Intraday Buy/Sell Signals
OCUL
Price
$11.45
Change
+$0.22 (+1.96%)
Updated
Oct 15, 11:16 AM (EDT)
Capitalization
2.38B
25 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

IMTX vs OCUL

Header iconIMTX vs OCUL Comparison
Open Charts IMTX vs OCULBanner chart's image
Immatics
Price$10.57
Change+$0.40 (+3.93%)
Volume$11.59K
Capitalization1.24B
Ocular Therapeutix
Price$11.45
Change+$0.22 (+1.96%)
Volume$200
Capitalization2.38B
IMTX vs OCUL Comparison Chart in %
IMTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMTX vs. OCUL commentary
Oct 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMTX is a Hold and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 16, 2025
Stock price -- (IMTX: $10.18 vs. OCUL: $11.21)
Brand notoriety: IMTX and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMTX: 58% vs. OCUL: 86%
Market capitalization -- IMTX: $1.24B vs. OCUL: $2.38B
IMTX [@Biotechnology] is valued at $1.24B. OCUL’s [@Biotechnology] market capitalization is $2.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMTX’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • IMTX’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than IMTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMTX’s TA Score shows that 4 TA indicator(s) are bullish while OCUL’s TA Score has 3 bullish TA indicator(s).

  • IMTX’s TA Score: 4 bullish, 4 bearish.
  • OCUL’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, IMTX is a better buy in the short-term than OCUL.

Price Growth

IMTX (@Biotechnology) experienced а +8.14% price change this week, while OCUL (@Biotechnology) price change was -2.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.44%. For the same industry, the average monthly price growth was +17.42%, and the average quarterly price growth was +81.94%.

Reported Earning Dates

IMTX is expected to report earnings on Nov 18, 2025.

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.38B) has a higher market cap than IMTX($1.24B). IMTX YTD gains are higher at: 43.122 vs. OCUL (31.265). IMTX has higher annual earnings (EBITDA): -58.05M vs. OCUL (-200.5M). IMTX has more cash in the bank: 478M vs. OCUL (391M). IMTX has less debt than OCUL: IMTX (17.1M) vs OCUL (76.9M). IMTX has higher revenues than OCUL: IMTX (130M) vs OCUL (56.7M).
IMTXOCULIMTX / OCUL
Capitalization1.24B2.38B52%
EBITDA-58.05M-200.5M29%
Gain YTD43.12231.265138%
P/E Ratio27.61N/A-
Revenue130M56.7M229%
Total Cash478M391M122%
Total Debt17.1M76.9M22%
FUNDAMENTALS RATINGS
IMTX vs OCUL: Fundamental Ratings
IMTX
OCUL
OUTLOOK RATING
1..100
2112
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
48
Fair valued
PROFIT vs RISK RATING
1..100
8888
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
3646
P/E GROWTH RATING
1..100
61100
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (48) in the Pharmaceuticals Other industry is in the same range as IMTX (73) in the null industry. This means that OCUL’s stock grew similarly to IMTX’s over the last 12 months.

OCUL's Profit vs Risk Rating (88) in the Pharmaceuticals Other industry is in the same range as IMTX (88) in the null industry. This means that OCUL’s stock grew similarly to IMTX’s over the last 12 months.

IMTX's SMR Rating (95) in the null industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that IMTX’s stock grew similarly to OCUL’s over the last 12 months.

IMTX's Price Growth Rating (36) in the null industry is in the same range as OCUL (46) in the Pharmaceuticals Other industry. This means that IMTX’s stock grew similarly to OCUL’s over the last 12 months.

IMTX's P/E Growth Rating (61) in the null industry is somewhat better than the same rating for OCUL (100) in the Pharmaceuticals Other industry. This means that IMTX’s stock grew somewhat faster than OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMTXOCUL
RSI
ODDS (%)
Bearish Trend 3 days ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
68%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 16 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IMTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRSHX26.06N/A
N/A
MFS Research International R3
BRSPX14.23N/A
N/A
MFS Blended Research Small Cap Eq R1
VRMGX63.32N/A
N/A
Virtus KAR Mid-Cap Growth R6
ATGRX14.12N/A
N/A
American Century International Gr R
AHSAX20.24N/A
N/A
Alger Health Sciences A

IMTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with IDYA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMTX
1D Price
Change %
IMTX100%
+0.85%
IDYA - IMTX
53%
Loosely correlated
+1.12%
SYRE - IMTX
50%
Loosely correlated
+11.02%
RLAY - IMTX
49%
Loosely correlated
-3.99%
OCUL - IMTX
49%
Loosely correlated
-5.40%
IMNM - IMTX
49%
Loosely correlated
-1.26%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-5.40%
EYPT - OCUL
64%
Loosely correlated
-1.35%
IDYA - OCUL
57%
Loosely correlated
+1.12%
DNLI - OCUL
54%
Loosely correlated
+1.34%
NUVL - OCUL
53%
Loosely correlated
-5.66%
NRIX - OCUL
53%
Loosely correlated
-5.61%
More